HpD photodynamic therapy for obstructing lung cancer.
Twenty-two patients with endobronchial cancer of the lungs have been treated with photoradiation therapy (PRT) employing a set protocol of 3.0 mg/kg hematoporphyrin derivative (HpD) administered intravenously 72 hours prior to red light (630 nm) illumination via a bronchoscope. Twenty patients showed a complete response. Of these, nineteen had large obstructing endobronchial tumors; one had a small mucosal lesion. Only one patient with an obstructing tumor showed a partial response. The one showing no response had an endobronchial mass that consisted of fibrous tissue, not tumor, as shown on three separate bronchoscopic biopsies.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D020680:Bronchoscopes; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects / Q000295:instrumentation*
D000970:Antineoplastic Agents; D006415:Hematoporphyrins; D017324:Hematoporphyrin Derivative